elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Acetazolamide
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Acetazolamide
RIS
0.001
(Research Intensity Score)
Papers
91
Top papers
Discovery of sulfadrug–pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors
2021 · 284 citations
Combination pharmacological therapy targeting multiple mechanisms of sleep apnoea: a randomised controlled cross-over trial
2024 · 30 citations
Review of the Diagnosis and Treatment of Periodic Paralysis
2017 · 264 citations
CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma
2025 · 8 citations
Green Synthesis of Gold Nanoparticles Using Extract of Pistacia chinensis and Their In Vitro and In Vivo Biological Activities
2022 · 33 citations
Newest papers
Late-Onset Episodic Weakness With Hyperkalemia Suggestive of Hyperkalemic Periodic Paralysis
2026
Idiopathic intracranial hypertension: a literature review
2026
Biological Evaluation, Molecular Docking, and in Ovo Hatchability Assessment of Selected Mannich-Type 1,2,4-Triazol-5-one Derivatives
2026
[Interpretation and reflections on the 2025 American Academy of Sleep Medicine clinical practice guideline for the treatment of central sleep apnea in adults].
2026
Fungal keratitis caused by a dematiaceous Pleosporales member following ocular trauma with a wooden fragment: a case report
2026
A sample from the 91 top papers behind Acetazolamide.
Create a free account to browse them all →
Acetazolamide's history
Research intensity over time
Explore Acetazolamide's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Acetazolamide's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link